Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers have challenged findings from a Chinese study that concluded Baraclude is tied to a lower risk of liver cancer.
New research shows that treating these viruses can reduce liver cancer risk.
Available vaccines offer protection against cervical, anal, oral, liver and stomach cancers.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
This finding may reflect higher rates of sexually transmitted infections such as HPV and hep B as well as lifestyle factors.
The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
People who receive chemotherapy for cancer have a higher risk of hep B reactivation.
Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.
Women with a history of the malignancy also survive longer than men after receiving a liver transplant.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
Sci-B-Vac may offer more protection for older people and those with a weaker immune system.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
Efforts to control viral hepatitis are falling behind, in part because of the growing opioid epidemic and homelessness crisis.
The change targets LGBT people and those with chronic conditions. Here’s how patient groups and Lambda Legal respond.
Help find the “missing millions” who don’t know they’re living with viral hepatitis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.